Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Pharmacoeconomics ; 34(8): 741-50, 2016 08.
Article in English | MEDLINE | ID: mdl-26892974

ABSTRACT

The National Institute for Health and Care Excellence (NICE) invited Gilead, the company manufacturing ledipasvir-sofosbuvir (LDV/SOF), to submit evidence for the clinical effectiveness and cost effectiveness of LDV/SOF for treating chronic hepatitis C. The School of Health and Related Research (ScHARR) Technology Assessment Group was commissioned as the Evidence Review Group (ERG). This paper describes the company's submission (CS), the ERG review and the subsequent decision of the NICE Appraisal Committee (AC). The ERG produced a critical review of the clinical effectiveness and cost-effectiveness evidence of LDV/SOF based upon the CS. The clinical effectiveness data for LDV/SOF were taken from ten trials: three phase III trials and seven phase II trials. Trials compared different durations of LDV/SOF, with and without ribavirin (RBV). There were no head-to-head trials comparing LDV/SOF with any comparator listed in the NICE scope. Data from the trials were mostly from populations with genotype 1 (GT1) disease, although some limited data were available for populations with genotypes 3 and 4. For GT1 treatment-naïve patients, sustained viral response for 12 weeks (SVR12) rates for LDV/SOF ranged from 93.1 to 99.4 % for subgroups of patients with non-cirrhotic disease, whilst SVR rates of 94.1 to 100 % were reported for subgroups of patients with compensated cirrhosis. For GT1 treatment-experienced patients, SVR12 rates ranging from 95.4 to 100 % were reported for subgroups of non-cirrhotic patients, and SVR rates ranging from 81.8 to 100 % were reported within subgroups of patients with compensated cirrhosis. Comparator data were not searched systematically as part of the submission, but were based on the company's previous NICE submission of sofosbuvir, with additional targeted searches. The ERG's critical appraisal of the company's economic evaluation highlighted a number of concerns. The ERG's base case analyses suggested that the incremental cost-effectiveness ratios (ICERs) for LDV/SOF (+RBV) are dependent on (a) treatment durations, (b) whether patients have been previously treated and (c) whether patients have liver cirrhosis or not. The AC concluded that it was appropriate to use the approach taken in the ERG's exploratory analyses, in line with the marketing authorisation, which considered people with and without cirrhosis separately, and estimated the cost effectiveness for each recommended treatment duration of LDV/SOF.


Subject(s)
Antiviral Agents/administration & dosage , Benzimidazoles/administration & dosage , Fluorenes/administration & dosage , Hepatitis C, Chronic/drug therapy , Uridine Monophosphate/analogs & derivatives , Antiviral Agents/economics , Benzimidazoles/economics , Cost-Benefit Analysis , Fluorenes/economics , Genotype , Hepacivirus/genetics , Hepatitis C, Chronic/economics , Hepatitis C, Chronic/virology , Humans , Liver Cirrhosis/drug therapy , Liver Cirrhosis/economics , Liver Cirrhosis/virology , Sofosbuvir , Time Factors , Uridine Monophosphate/administration & dosage , Uridine Monophosphate/economics
2.
Br J Surg ; 101(9): 1040-52, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24964976

ABSTRACT

BACKGROUND: A Health Technology Assessment was conducted to evaluate the relative clinical effectiveness and cost-effectiveness of minimally invasive techniques (foam sclerotherapy (FS), endovenous laser ablation (EVLA) and radiofrequency ablation (RFA)) for managing varicose veins, in comparison with traditional surgery. METHODS: A systematic review of randomized clinical trials (RCTs) was undertaken to assess the effectiveness of minimally invasive techniques compared with other treatments, principally surgical stripping, in terms of recurrence of varicose veins, Venous Clinical Severity Score (VCSS), pain and quality of life. Network meta-analysis and exploratory cost-effectiveness modelling were performed. RESULTS: The literature search conducted in July 2011 identified 1453 unique citations: 31 RCTs (51 papers) satisfied the criteria for effectiveness review. Differences between treatments were negligible in terms of clinical outcomes, so the treatment with the lowest cost appears to be most cost-effective. Total FS costs were estimated to be lowest, and FS was marginally more effective than surgery. However, relative effectiveness was sensitive to the model time horizon. Threshold analysis indicated that EVLA and RFA might be considered cost-effective if their costs were similar to those for surgery. These findings are subject to various uncertainties, including the risk of bias present in the evidence base and variation in reported costs. CONCLUSION: This assessment of currently available evidence suggests there is little to choose between surgery and the minimally invasive techniques in terms of efficacy or safety, so the relative cost of the treatments becomes one of the deciding factors. High-quality RCT evidence is needed to verify and further inform these findings.


Subject(s)
Varicose Veins/therapy , Adult , Catheter Ablation/adverse effects , Catheter Ablation/economics , Cost-Benefit Analysis , Humans , Laser Therapy/adverse effects , Laser Therapy/economics , Middle Aged , Pain/economics , Pain/etiology , Pain Measurement , Quality-Adjusted Life Years , Randomized Controlled Trials as Topic , Recurrence , Sclerotherapy/adverse effects , Sclerotherapy/economics , Technology Assessment, Biomedical , Varicose Veins/economics
6.
Health Technol Assess ; 17(48): i-xvi, 1-141, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24176098

ABSTRACT

BACKGROUND: Varicose veins are enlarged, visibly lumpy knotted veins, usually in the legs. Uncomplicated varicose veins can cause major discomfort and some complications. They are part of chronic venous disease (CVD), which is reported to have a substantial negative impact on health-related quality of life (HRQoL). Traditional treatments for varicose veins involve surgical stripping and ligation and liquid sclerotherapy (LS), but can be invasive and painful. New minimally invasive treatments offer an alternative. These treatments typically involve use of laser, radiofrequency or foam sclerosant. They are increasingly widely used and offer potential benefits such as reduced complications, faster recovery, fewer physical limitations and improved quality of life. OBJECTIVE: The aim of this report is to evaluate the clinical effectiveness, safety and cost-effectiveness of the minimally invasive techniques of foam sclerotherapy (FS), endovenous laser ablation (EVLA) and radiofrequency ablation (RFA) in comparison with other techniques, including traditional surgical techniques, LS and conservative management, in the management of varicose veins. DATA SOURCES: A systematic search was made of 11 bibliographic databases of published and unpublished literature from their inception to July 2011: MEDLINE; EMBASE; Cumulative Index to Nursing and Allied Health Literature; The Cochrane Library; Biological Abstracts; Science Citation Index (SCI); Social Sciences Citation Index; Conference Proceedings Citation Index-Science; UK Clinical Research Network; Current Controlled Trials; and ClinicalTrials.gov. REVIEW METHODS: A systematic review of randomised controlled trials (RCTs) to assess the clinical effectiveness of minimally invasive techniques compared with other treatments, principally surgical stripping, in terms of recurrence of varicose veins, retreatment and clinical symptoms, as measured by the Venous Clinical Severity Score (VCSS), pain and quality of life. Network meta-analysis and exploratory cost-effectiveness modelling were performed. RESULTS: The literature search identified 1453 unique citations, of which 34 RCTs (54 papers) satisfied the criteria for the clinical effectiveness review. The minimally invasive techniques reported clinical outcomes similar to surgery. Rates of recurrence were slightly lower for EVLA, RFA and FS, especially for longer follow-up periods; VCSS score was lower for EVLA and FS than for stripping, but slightly higher for RFA; short-term pain was less for FS and RFA but higher for EVLA; higher quality-of-life scores were reported for all evaluated interventions than for stripping. Differences between treatments were therefore negligible in terms of clinical outcomes, so the treatment with the lowest cost appears to be most cost-effective. Our central estimate is that total FS costs were lowest and FS is marginally more effective than stripping. However, this result was sensitive to the model time horizon. Threshold analysis indicated that EVLA and RFA might be considered cost-effective if their costs are equivalent to stripping. These findings are subject to uncertainty on account of the risk of bias present in the evidence base and the variation in costs. LIMITATIONS: The relative clinical effectiveness and cost-effectiveness of the techniques are principally based on rates of post-operative technical recurrence rather than symptomatic recurrence, as this was the reported outcome in all trials. The true proportion of treated individuals who are likely to present with symptoms of recurrence requiring retreatment is therefore not certain. A figure reflecting the likely proportion of treated individuals who would experience symptomatic recurrence requiring retreatment (with its associated costs), therefore, had to be calculated by the authors based on a small number of studies. The findings of this report also need to be verified by data from future trials with longer follow-up and using more standardised outcome measures. CONCLUSIONS: This assessment of the currently available evidence suggests there is little to choose between the minimally invasive techniques in terms of efficacy or cost, and each offers a viable, clinically effective alternative to stripping. FS might offer the most cost-effective alternative to stripping, within certain time parameters. High-quality RCT evidence is needed. Future trials should aim to measure and report outcomes in a standardised manner, which would permit more efficient pooling of their results. STUDY REGISTRATION: PROSPERO number CRD42011001355. FUNDING: The National Institute for Health Research Health Technology Assessment programme.


Subject(s)
Catheter Ablation/economics , Laser Therapy/economics , Sclerotherapy/economics , Varicose Veins/therapy , Catheter Ablation/methods , Cost-Benefit Analysis , Health Expenditures , Humans , Laser Therapy/methods , Quality-Adjusted Life Years , Randomized Controlled Trials as Topic , Recurrence , Sclerotherapy/methods
7.
Health Technol Assess ; 17(32): 1-207, v-vi, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23927840

ABSTRACT

BACKGROUND: Remote monitoring (RM) strategies have the potential to deliver specialised care and management to patients with heart failure (HF). OBJECTIVE: To determine the clinical effectiveness and cost-effectiveness of home telemonitoring (TM) or structured telephone support (STS) strategies compared with usual care for adult patients who have been recently discharged (within 28 days) from acute care after a recent exacerbation of HF. DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE, PsycINFO and The Cochrane Library) and research registers were searched to January 2012, supplemented by hand-searching relevant articles and contact with experts. The review included randomised controlled trials (RCTs) or observational cohort studies with a contemporaneous control group that included the following RM interventions: (1) TM (including cardiovascular implanted monitoring devices) with medical support provided during office hours or 24/7; (2) STS programmes delivered by human-to-human contact (HH) or human-to-machine interface (HM). REVIEW METHODS: A systematic review and network meta-analysis (where appropriate) of the clinical evidence was carried out using standard methods. A Markov model was developed to evaluate the cost-effectiveness of different RM packages compared with usual care for recently discharged HF patients. TM 24/7 or using cardiovascular monitoring devices was not considered in the economic model because of the lack of data and/or unsuitability for the UK setting. Given the heterogeneity in the components of usual care and RM interventions, the cost-effectiveness analysis was performed using a set of costing scenarios designed to reflect the different configurations of usual care and RM in the UK. RESULTS: The literature searches identified 3060 citations. Six RCTs met the inclusion criteria and were added to the 15 trials identified from the previous systematic reviews giving a total of 21 RCTs included in the systematic review. No trials of cardiovascular implanted monitoring devices or observational studies met the inclusion criteria. The methodological quality of the studies varied widely and reporting was generally poor. Compared with usual care, RM was beneficial in reducing all-cause mortality for STS HH [hazard ratio (HR) 0.77, 95% credible interval (CrI) 0.55 to 1.08], TM during office hours (HR 0.76, 95% CrI 0.49 to 1.18) and TM 24/7 (HR 0.49, 95% CrI 0.20 to 1.18); however, these results were statistically inconclusive. The results for TM 24/7 should be treated with caution because of the poor methodological quality of the only included study in this network. No favourable effect on mortality was observed with STS HM. Similar reductions were observed in all-cause hospitalisations for TM interventions, whereas STS interventions had no major effect. A sensitivity analysis, in which a study was excluded because it provided better-than-usual support to the control group, showed larger beneficial effects for most outcomes, particularly for TM during office hours. In the cost-effectiveness analyses, TM during office hours was the most cost-effective strategy with an estimated incremental cost-effectiveness ratio (ICER) of £11,873 per quality-adjusted life-year (QALY) compared with usual care, whereas STS HH had an ICER of £228,035 per QALY compared with TM during office hours. STS HM was dominated by usual care. Similar results were observed in scenario analyses performed using higher costs of usual care, higher costs of STS HH and lower costs of TM during office hours. LIMITATIONS: The RM interventions included in the review were heterogeneous in terms of monitored parameters and HF selection criteria and lacked detail in the components of the RM care packages and usual care (e.g. communication protocols, routine staff visits and resources used). As a result, the economic model developed scenarios for different RM classifications and their costs were estimated using bottom-up costing methods. Although the users can decide which of these scenarios is most representative of their setting, uncertainties still remain about the assumptions made in the estimation of these costs. In addition, the model assumed that the effectiveness of the interventions was constant over time, irrespective of the duration of deployment, and that the intervention was equally effective in different age/severity groups. CONCLUSION: Despite wide variation in usual care and RM strategies, cost-effectiveness analyses suggest that TM during office hours was an optimal strategy (in most costing scenarios). However, clarity was lacking among descriptions of the components of RM packages and usual care and there was a lack of robust estimation of costs. Further research is needed in these areas. STUDY REGISTRATION: PROSPERO registration no. CRD42011001368. FUNDING: The National Institute for Health Research Health Technology Assessment programme.


Subject(s)
Heart Failure/therapy , Home Care Services/organization & administration , Monitoring, Physiologic/methods , Telemedicine/methods , Telephone , Cost-Benefit Analysis , Heart Failure/diagnosis , Heart Failure/economics , Home Care Services/economics , Humans , Markov Chains , Monitoring, Physiologic/economics , Patient Discharge , Patient Readmission , Telemedicine/economics
8.
Health Technol Assess ; 17(1): v-vi, 1-188, 2013.
Article in English | MEDLINE | ID: mdl-23331845

ABSTRACT

BACKGROUND: Current practice for suspected acute coronary syndrome (ACS) involves troponin testing 10-12 hours after symptom onset to diagnose myocardial infarction (MI). Patients with a negative troponin can be investigated further with computed tomographic coronary angiography (CTCA) or exercise electrocardiography (ECG). OBJECTIVES: We aimed to estimate the diagnostic accuracy of early biomarkers for MI, the prognostic accuracy of biomarkers for major adverse cardiac adverse events (MACEs) in troponin-negative patients, the diagnostic accuracy of CTCA and exercise ECG for coronary artery disease (CAD) and the prognostic accuracy of CTCA and exercise ECG for MACEs in patients with suspected ACS. We then aimed to estimate the cost-effectiveness of using alternative biomarker strategies to diagnose MI, and using biomarkers, CTCA and exercise ECG to risk-stratify troponin-negative patients. DATA SOURCES: We searched MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations; Cumulative Index of Nursing and Allied Health Literature (CINAHL), EMBASE, Web of Science, Cochrane Central Database of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), NHS Database of Abstracts of Reviews of Effects (DARE) and the Health Technology Assessment database from 1985 (CTCA review) or 1995 (biomarkers review) to November 2010, reviewed citation lists and contacted experts to identify relevant studies. REVIEW METHODS: Diagnostic studies were assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool and prognostic studies using a framework adapted for the project. Meta-analysis was conducted using bayesian Markov chain Monte Carlo simulation. We developed a decision-analysis model to evaluate the cost-effectiveness of alternative biomarker strategies to diagnose MI, and the cost-effectiveness of biomarkers, CTCA or exercise ECG to risk-stratify patients with a negative troponin. Strategies were applied to a theoretical cohort of patients with suspected ACS. Cost-effectiveness was estimated as the incremental cost per quality-adjusted life-year (QALY) of each strategy compared with the next most effective, taking a health-service perspective and a lifetime horizon. RESULTS: Sensitivity and specificity (95% predictive interval) were 77% (29-96%) and 93% (46-100%) for troponin I, 80% (33-97%) and 91% (53-99%) for troponin T (99th percentile threshold), 81% (50-95%) and 80% (26-98%) for quantitative heart-type fatty acid-binding protein (H-FABP), 68% (11-97%) and 92% (20-100%) for qualitative H-FABP, 77% (19-98%) and 39% (2-95%) for ischaemia-modified albumin and 62% (35-83%) and 83% (35-98%) for myoglobin. CTCA had 94% (61-99%) sensitivity and 87% (16-100%) specificity for CAD. Positive CTCA and positive-exercise ECG had relative risks of 5.8 (0.6-24.5) and 8.0 (2.3-22.7) for MACEs. In most scenarios in the economic analysis presentation, high-sensitivity troponin measurement was the most effective strategy with an incremental cost-effectiveness ratio (ICER) of less than the £20,000-30,000/QALY threshold (ICER £7487-17,191/QALY). CTCA appeared to be the most cost-effective strategy for patients with a negative troponin, with an ICER of £11,041/QALY. However, when a lower MACE rate was assumed, CTCA had a high ICER (£262,061/QALY) and the no-testing strategy was optimal. LIMITATIONS: There was substantial variation between the primary studies and heterogeneity in their results. Findings of the economic model were dependent on assumptions regarding the value of detecting and treating positive cases. CONCLUSIONS: Although presentation troponin has suboptimal sensitivity, measurement of a 10-hour troponin level is unlikely to be cost-effective in most scenarios compared with a high-sensitivity presentation troponin. CTCA may be a cost-effective strategy for troponin-negative patients, but further research is required to estimate the effect of CTCA on event rates and health-care costs. FUNDING: The National Institute for Health Research Health Technology Assessment programme.


Subject(s)
Acute Coronary Syndrome/blood , Acute Coronary Syndrome/diagnosis , Models, Econometric , Myocardial Infarction/blood , Myocardial Infarction/diagnosis , Bayes Theorem , Biomarkers/blood , Cost-Benefit Analysis , Decision Support Techniques , Electrocardiography , Exercise Test , Fatty Acid Binding Protein 3 , Fatty Acid-Binding Proteins/blood , Humans , Myoglobin/blood , Prognosis , Quality-Adjusted Life Years , Sensitivity and Specificity , Serum Albumin , Serum Albumin, Human , Troponin T/blood
9.
Br J Surg ; 99(12): 1630-8, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23034699

ABSTRACT

BACKGROUND: A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD). METHODS: MEDLINE, Embase, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Conference Proceedings, BIOSIS, National Research Register and MetaRegister databases were searched. Eligible studies were randomized controlled trials (RCTs) and published systematic reviews of patients with intermittent claudication due to PAD and whose symptoms persisted despite a period of conservative management. Study selection was conducted by one reviewer with involvement from a clinician. Data were extracted by one reviewer with no blinding to authors or journal, and checked by a second reviewer. Outcome measures were maximum walking distance (MWD) and pain-free walking distance (PFWD). RESULTS: The review identified 1876 citations; 26 RCTs met the inclusion criteria for the systematic review. Eleven trials provided data relevant for the meta-analysis. Naftidrofuryl oxalate was ranked first for both MWD and PFWD (probability of 0·947 and 0·987, respectively, of being the best treatment) followed by cilostazol and pentoxifylline. For naftidrofuryl oxalate, cilostazol and pentoxifylline, MWD increased by 60 (95 per cent credible interval 20 to 114) per cent, 25 (11 to 40) per cent and 11 (-1 to 24) per cent respectively relative to placebo, and PFWD increased by 49, 13 and 9 per cent. CONCLUSION: Naftidrofuryl oxalate and cilostazol are both effective treatments for claudication; naftidrofuryl oxalate is likely to be the most effective, with minimal serious adverse events.


Subject(s)
Intermittent Claudication/drug therapy , Nafronyl/therapeutic use , Pentoxifylline/therapeutic use , Peripheral Vascular Diseases/complications , Tetrazoles/therapeutic use , Vasodilator Agents/therapeutic use , Cilostazol , Humans , Intermittent Claudication/etiology , Intermittent Claudication/physiopathology , Pain/prevention & control , Peripheral Vascular Diseases/physiopathology , Randomized Controlled Trials as Topic , Treatment Outcome , Walking/physiology
10.
Health Technol Assess ; 15 Suppl 1: 69-75, 2011 May.
Article in English | MEDLINE | ID: mdl-21609655

ABSTRACT

The paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of trabectedin for the treatment of relapsed platinum-sensitive ovarian cancer, based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. The submission addressed only part of the decision problem and did not provide evidence to compare trabectedin (Yondelis®, PharmaMar) and pegylated liposomal doxorubicin hydrochloride (PLDH) (Caelyx®, Schering-Plough) with key comparators. The submission's direct comparison evidence came from one reasonable-quality randomised controlled trial (RCT) of trabectedin and PLDH versus PLDH alone (ET743-OVA-301). The results of the RCT were subdivided into the entire platinum-sensitive population (> 6-month relapse after initial platinum-based chemotherapy) and partially platinum-sensitive (≥ 6- to 12-month relapse) and fully platinum-sensitive (> 12-month relapse) populations. The outcomes included were overall survival, progression-free survival measured by three types of assessor, response rates, adverse effects of treatment, health-related quality of life and cost per quality-adjusted-life-year (QALY) gained. A mixed treatment comparison (MTC) meta-analysis comparing trabectedin and PLDH with single-agent PLDH within the entire platinum-sensitive population, with paclitaxel or with topotecan also formed part of the submission. The RCT data showed that trabectedin plus PLDH compared with PLDH monotherapy had a significant effect on overall survival only within the partially platinum-sensitive subgroup. PFS results reported by the independent radiologists showed significant effects in favour of the trabectedin and PLDH arm for the entire and partially platinum-sensitive populations only. Rates of grade 3 and 4 adverse events were mostly higher in the trabectedin and PLDH arm than in the PLDH alone arm. There were several issues regarding the undertaking of the MTC, and thus the data were not considered robust. Furthermore, the ERG did not believe the MTC to be necessary to answer the decision problem. The manufacturer submitted a de novo cost-effectiveness model. The main analysis compared trabectedin in combination with PLDH versus paclitaxel, topotecan and PLDH (each as monotherapy) in the entire platinum-sensitive population, using results estimated from the MTC. Additional analyses were presented comparing trabectedin in combination with PLDH versus PLDH monotherapy using direct evidence from the OVA-301 trial for the fully, partially and entire platinum-sensitive populations. The cost per QALY gained for trabectedin in combination with PLDH versus PLDH monotherapy was estimated to be £ 70,076 in the main analysis. In the additional analyses, the cost per QALY gained for trabectedin in combination with PLDH versus PLDH monotherapy was £ 94,832, £ 43,996 and £ 31,092 for the entire, partially and fully platinum-sensitive populations, respectively. Additional work was undertaken by the ERG using patient-level data and amending some assumptions to provide a better statistical fit to the Kaplan-Meier data than the exponential distribution assumed by the manufacturer. The ERG base-case estimate of the cost per QALY of trabectedin in combination with PLDH ranged from £46,503 to £54,607 in the partially platinum-sensitive population. At the time of writing, trabectedin in combination with PLDH for the treatment of women with relapsed platinum-sensitive ovarian cancer is not recommended by NICE in the final appraisal determination.


Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Dioxoles/therapeutic use , Neoplasm Recurrence, Local/drug therapy , Ovarian Neoplasms/drug therapy , Tetrahydroisoquinolines/therapeutic use , Antineoplastic Agents, Alkylating/economics , Dioxoles/economics , Doxorubicin/analogs & derivatives , Doxorubicin/therapeutic use , Female , Humans , Mesalamine , Meta-Analysis as Topic , Polyethylene Glycols/therapeutic use , Quality of Life , Quality-Adjusted Life Years , Randomized Controlled Trials as Topic , Survival Analysis , Tetrahydroisoquinolines/economics , Trabectedin
11.
ISA Trans ; 43(4): 491-7, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15535389

ABSTRACT

Accurately determining the effect of the propagation of uncertainty in nonlinear applications can be awkward and difficult. The Monte Carlo approach requires statistically significant numbers of function evaluations (typically 10(5) or more) and analytical methods are intractable for all but the simplest cases. This paper derives and demonstrates a method to estimate the propagation of uncertainty in nonlinear cases by representing the function in a piecewise fashion with straight line segments. The probability density function of the result can be calculated from the transformation of the line segments. The mean and confidence intervals of the result can then be calculated from the probability density function. For the special case of a normal distribution in the independent variable, calculation of the mean and confidence intervals requires evaluation of only the error function (erf). A simple example is presented to demonstrate the technique. Variations on the basic approach are presented and discussed.


Subject(s)
Algorithms , Models, Statistical , Nonlinear Dynamics , Numerical Analysis, Computer-Assisted , Stochastic Processes , Computer Simulation
12.
Stat Med ; 21(20): 3023-33, 2002 Oct 30.
Article in English | MEDLINE | ID: mdl-12369079

ABSTRACT

In a complex seven-period cross-over trial to study the effects of a drug in attenuating capsaicin-induced coughing, counts of numbers of coughs were recorded 32 times in each period. Subjects were subjected to four escalating levels of capsaicin at each of one and five hours after treatment, with counts of coughs being recorded in four one-minute intervals at each level. Such longitudinal count studies often show considerable individual variability about any regression curve that might be fitted. We develop a non-linear autoregressive model for such count data that also allows for overdispersion.


Subject(s)
Cough/drug therapy , Cross-Over Studies , Models, Statistical , Thiazoles/pharmacology , Adrenergic beta-Agonists/pharmacology , Albuterol/pharmacology , Capsaicin/administration & dosage , Cough/chemically induced , Domperidone/pharmacology , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Female , Humans , Longitudinal Studies , Male , Receptors, Dopamine D2/agonists
13.
Stat Methods Med Res ; 11(6): 469-90, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12516985

ABSTRACT

We review the development of Bayesian statistical methods for the design and analysis of randomized controlled trials in the assessment of the cost-effectiveness of health care technologies. We place particular emphasis on the benefits of the Bayesian approach; the implications of skew cost data; the need to model the data appropriately to generate efficient and robust inferences instead of relying on distribution-free methods; the importance of making full use of quantitative and structural prior information to produce realistic inferences; and issues in the determination of sample size. Several new examples are presented to illustrate the methods. We conclude with a discussion of the key areas for future research.


Subject(s)
Bayes Theorem , Cost-Benefit Analysis/methods , Technology Assessment, Biomedical/methods , Arthritis/therapy , Asthma/drug therapy , Chronic Disease , Cost-Benefit Analysis/statistics & numerical data , Data Interpretation, Statistical , Health Services Research/economics , Health Services Research/methods , Health Services Research/statistics & numerical data , Heart Failure/drug therapy , Humans , Randomized Controlled Trials as Topic/economics , Randomized Controlled Trials as Topic/statistics & numerical data , Research Design , Technology Assessment, Biomedical/economics
14.
Med Decis Making ; 21(3): 219-30, 2001.
Article in English | MEDLINE | ID: mdl-11386629

ABSTRACT

The authors present an analysis of the choice of sample sizes for demonstrating cost-effectiveness of a new treatment or procedure, when data on both cost and efficacy will be collected in a clinical trial. The Bayesian approach to statistics is employed, as well as a novel Bayesian criterion that provides insight into the sample size problem and offers a very flexible formulation.


Subject(s)
Bayes Theorem , Clinical Trials as Topic/statistics & numerical data , Cost-Benefit Analysis/statistics & numerical data , Sample Size , Economics, Pharmaceutical , Humans , Research Design
15.
Health Econ ; 10(4): 303-15, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11400253

ABSTRACT

We present a general Bayesian framework for cost-effectiveness analysis (CEA) from clinical trial data. This framework allows for very flexible modelling of both cost and efficacy related trial data. A common CEA technique is established for this wide class of models through linking mean efficacy and mean cost to the parameters of any given model. Examples are given in which efficacy may be measured as a continuous, binary, ordinal or time-to-event outcome, and in which costs are modelled as distributed normally, log-normally, as a mixture or non-parametrically. A case study is presented, illustrating the methodology and illuminating the role of prior information.


Subject(s)
Cost-Benefit Analysis/methods , Randomized Controlled Trials as Topic/economics , Bayes Theorem , Data Interpretation, Statistical , Humans , Models, Econometric , State Medicine , United Kingdom
16.
Subst Use Misuse ; 36(4): 421-46, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11346275

ABSTRACT

Currently, the profession of social work has proclaimed the need for an empirical research agenda to broaden its knowledge base. The profession's positivists rightly argue that a sound knowledge base is derived from rigorous scientific empirical methods. Unquestionably, the profession's unique contribution to the study of human development has been its emphasis on environmental effects and individual adaptation. Presently, social scientists embrace an ecological perspective when studying how social environmental effects are mediated. As researchers shift to a social ecological perspective, an empirical contextual model will allow the study of racial/ethnic differences in the incidence of adolescent problem behaviors (Stevens, 1998). An examination of the social ecology of poor, urban black female adolescents was undertaken to examine claims of the co-occurrence of early coitus and substance use, behaviors evident in black adolescents. An ecological framework operationalized by the constructs structural strain, kinscriptions, and community bridging is used to explicate how coital behavior among black females may not co-occur with drug use. The article's exegesis is directed by four postulates that help clarify the relationship of social ecology to the linkage of early coital behavior and substance use. The article concludes with adolescent narratives that illumine the cogency of the ecological analysis.


Subject(s)
Coitus/physiology , Social Environment , Substance-Related Disorders/psychology , Adolescent , Adolescent Behavior , Age Factors , Coitus/psychology , Female , Humans , Psychological Theory , Socioeconomic Factors , Urban Population/statistics & numerical data
17.
Stat Med ; 20(5): 733-53, 2001 Mar 15.
Article in English | MEDLINE | ID: mdl-11241573

ABSTRACT

A key tool for assessing the relative cost-effectiveness of two treatments in health economics is the incremental C/E acceptability curve. We present Bayesian computations for this curve in the case where data on both costs and efficacy are available from a clinical trial. Analysis is given under various formulations of prior information. A case study is analysed in which reasonable prior information is shown to strengthen substantially the posterior inference, leading to a more conclusive assessment of cost-effectiveness. Calculations can be performed using readily available Bayesian software.


Subject(s)
Bayes Theorem , Cost-Benefit Analysis/methods , Models, Economic , Randomized Controlled Trials as Topic/economics , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/economics , Asthma/drug therapy , Asthma/economics , Humans , Multicenter Studies as Topic , Nebulizers and Vaporizers
18.
Dev Dyn ; 219(3): 381-90, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11066094

ABSTRACT

CD44 has been identified at the time of extracellular matrix formation and expansion in several sites of the developing embryo (Wheatley et al. [1993] Development 119:295-306). The nucleus pulposus, consisting of a hydrated extracellular matrix tissue at birth, not previously closely analyzed, was examined for expression of CD44 in the developing and aging rat intervertebral disc. CD44 was identified solely on notochordal cells from the first onset of intervertebral disc formation (day 15 embryo) through the loss of notochordal cells from the nucleus pulposus (12-24 months of age). No CD44 expression was found in the notochordal cells prior to disc formation or in any cells other than the notochordal cells in the annulus fibrosus or nucleus pulposus of the intervertebral disc. Using reverse transcriptase-polymerase chain reaction methodology, the single 365 amino acid CD44 standard, CD44s, open reading frame was amplified from notochordal cells isolated from the nucleus pulposus. Western blot analysis of a cultured nucleus pulposus notochordal cells total protein extract identified a single CD44 species devoid of chondroitin sulfate with a mass of approximately 85 kDa, characteristic of CD44s. Cell surface detection for CD44 was co-localized with hyaluronan and proteoglycans at first appearance of disc formation in the nucleus pulposus.


Subject(s)
Hyaluronan Receptors/metabolism , Intervertebral Disc/embryology , Intervertebral Disc/immunology , Animals , Base Sequence , DNA Primers/genetics , Gene Expression Regulation, Developmental , Hyaluronan Receptors/genetics , Intervertebral Disc/growth & development , Microscopy, Electron , Notochord/cytology , Notochord/embryology , Notochord/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction
19.
Soc Work ; 45(4): 327-38, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10932932

ABSTRACT

An important component of welfare reform aimed at minor teenage parents is a requirement that the teenager live in an appropriate living situation, typically with a parent or guardian. The State of Massachusetts developed Teen Living Programs as an alternate living arrangement for minor teenage parents receiving welfare who are unable to live with family members. This article reports on a survey of 199 teenage parents who lived in the Teen Living Programs. Three research questions were asked: Who are the teenagers served by these programs? What services were provided? To what extent have teenagers attained key outcomes? Outcomes measured included educational attainment, employment, welfare status, homelessness, and subsequent pregnancy. Implications for social policy, further program development, and clinical intervention are discussed.


Subject(s)
Adolescent , Mothers/statistics & numerical data , Residential Facilities/statistics & numerical data , Social Welfare , Female , Humans , Massachusetts , Outcome Assessment, Health Care , Pregnancy , Pregnancy in Adolescence , Program Evaluation , Social Welfare/legislation & jurisprudence
20.
Pharmacoeconomics ; 17(4): 339-49, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10947489

ABSTRACT

The aim of this article is to consider Bayesian and frequentist inference methods for measures of incremental cost effectiveness in data obtained via a clinical trial. The most useful measure is the cost-effectiveness (C/E) acceptability curve. Recent publications on Bayesian estimation have assumed a normal posterior distribution, which ignores uncertainty in estimated variances, and suggest unnecessarily complicated methods of computation. We present a simple Bayesian computation for the C/E acceptability curve and a simple frequentist analogue. Our approach takes account of errors in estimated variances, resulting in calculations that are based on distributions rather than normal distributions. If inference is required about the C/E ratio, we argue that the standard frequentist procedures give unreliable or misleading inferences, and present instead a Bayesian interval.


Subject(s)
Bayes Theorem , Cost-Benefit Analysis , Antirheumatic Agents/economics , Antirheumatic Agents/therapeutic use , Clinical Trials as Topic/economics , Humans , Interleukin 1 Receptor Antagonist Protein , Sialoglycoproteins/economics , Sialoglycoproteins/therapeutic use , Survival Rate , Systemic Inflammatory Response Syndrome/drug therapy , Systemic Inflammatory Response Syndrome/economics , Systemic Inflammatory Response Syndrome/mortality
SELECTION OF CITATIONS
SEARCH DETAIL
...